Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance

Leukemia and Lymphoma

Volumn 28, Issue 3-4, 1998, Pages 355-361

  Pepper, Chris ^a   Hoy, Terry ^b   Bentley, Paul ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; Bax; Bcl 2; Chemoresistance; Chronic lymphocytic leukaemia

Indexed keywords

CHLORAMBUCIL; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL VIABILITY; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031929376     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809092690     Document Type: Article

References (24)

1. Dameshek, W. (1967). Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood, 29, 566-584.
2. McConkey, D. J., Aguilar-Santelises, M., Hartzell, P., et al. (1991). Induction of DNA cleavage in chronic B-lymphocytic leukemia cells. J Immunol., 146, 1072-1076.
3. Robertson, L. E., Chubb, S., Meyn, R. E., et al. (1993). Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoradenine. Blood, 81, 143-150.
4. Reed, J. C. (1995). Bcl-2 family proteins: regulators of chemoresistance in cancer Toxicology Letters, 82/83, 155-158.
5. L and interleukin-1β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia, 10 (suppl. 3), 18-22.
6. Nishiuchi, R., Yoshino, T., Matsuo, Y., et al. (1996). The Fas antigen is detected on immature B-cells and the representative cell lines show fas-mediated apoptosis. Br. J. Haem., 92, 302-307.
7. Lotem, J. and Sachs, L. (1993). Regulation by Bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and defective myeloid leukemic cells. Cell growth & Diff., 4, 41-47.
8. Macleod, K. F., Sherry, N., Hannon, G., et al. (1995). p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9, 935-944.
9. Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J. (1993). Bcl-2 heterodimerizes in vitro with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-619.
10. Chittenden, T., Harrington, E. A., O'Connor, R. et al. (1995). Induction of apoptosis by the Bcl-2 homologue Bak. Nature, 374, 733-736.
11. Miyashita, T. and Reed, J. C. (1992). Bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52, 5407-5411.
12. Kitada, S., Takayama, S., DeRiel, K., et al. (1994). Reversal of chemoresistance of lymphoma cells by antisense mediated reduction of Bcl-2 gene expression. Antisense Res. Dev., 4, 71-79.
13. Krajewski, S., Blomqvist, C., Franssila, K., et al. (1995). Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55, 4471-4478.
14. Hanada, M., Delia, D., Aiello, A., et al. (1993). Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood, 82(6), 1820-1828.
15. Robertson, L. E., Plunkett, W., McConnell, K., et al. (1996). Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia, 10, 456-459.
16. Pepper, C., Bentley, P. and Hoy, T. (1996). Regulation of clinical chemoresistance by Bcl-2 and Bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br. J. Haematol., 95, 513-517.
17. Korsmeyer, S. J., Shutter, J. R., Veis, D. J. et al. (1993). Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Seminars in Cancer Biol., 4, 327-332.
18. Cheson, B. D., Bennett, J. M., Rai, K. R., et al. (1988). Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored Working Group. Am. J. Haematol., 29, 152-163.
19. Binet, J. L., Auquier, A., Dighiero, G., et al. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
20. Gaidano, G., Newcomb, E. W., Gong, J. Z., et al. (1994). Analysis of alterations of oncogenes and tumour suppressor genes in chronic lymphocytic leukemia. Am. J. Pathol., 144, 1312-1319.
21. Panayiotidis, P., Ganeshaguru, K., Jabbar, S. A. B., et al. (1993). Interleukin-4 inhibits apoptotic cell death and loss of the Bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol., 85, 439-445.
22. Jewell, A. P., Worman, C. P., Lydyard, P. M. et al. (1994). Interferon-alpha up-regulates Bcl-2 expression and protects B-cells from apoptosis in vitro and in vivo. Br J. Haematol., 88, 268-274.
23. Holder, M. J., Wang, H., Milner, A. E. et al. (1993). Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction. Eur. J. Immunol., 23, 2368-2371.
24. Wang, H-G., Rapp, U. R. and Reed, J. C. (1996). Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell, 87, 629-638.